Thomas Neff, FibroGen
August 26, 2019 09:03 AM EDTUpdated 11:40 AM
R&D

Fi­bro­Gen founder and CEO Thomas Neff dies un­ex­pect­ed­ly as lead drug nears com­mer­cial thresh­old

John Carroll

Editor & Founder

Fi­bro­Gen founder and CEO Thomas Neff died “un­ex­pect­ed­ly” over the week­end, says the biotech com­pa­ny.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Keros halts parts of Phase 2 PAH tri­al due to safe­ty, stock tanks 70%

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Cor­cept’s ALS drug fails to im­prove func­tion in Phase 2 study

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

The End­points 100: The biotech in­dus­try braces for Trump 2.0

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times